sizofiran has been researched along with Ovarian Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (83.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, Y | 1 |
| Ohara, N; Teramoto, K | 1 |
| Adachi, T; Hoshino, T; Suzuki, Y; Takayama, M; Takeichi, M; Yagishita, M | 1 |
| Adachi, T; Hoshino, T; Suzuki, Y; Takayama, M; Yagishita, M | 1 |
| Inoue, M; Karita, T; Minagawa, J; Nakamuro, K; Okudaira, Y; Sugita, N; Tanaka, Y; Tani, T; Yamanaka, T; Yamasaki, M | 1 |
| Imaishi, K; Kataoka, A; Kumagai, S; Nishida, T; Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Adachi, T; Hoshino, T; Suzuki, Y; Takayama, M; Takeichi, M | 1 |
| Chen, JT; Hasumi, K; Masubuchi, K | 3 |
| Chen, JT; Hasumi, K; Masubuchi, K; Shimizu, Y; Teshima, H | 1 |
| Chen, JT; Hasumi, K; Masubuchi, K; Shimizu, Y; Suzuki, M; Teshima, H | 1 |
1 review(s) available for sizofiran and Ovarian Neoplasms
| Article | Year |
|---|---|
[Phase III study of gynecologic cancer in Japan].
Topics: Adjuvants, Immunologic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Combinations; Female; Genital Neoplasms, Female; Humans; Japan; Multicenter Studies as Topic; Ovarian Neoplasms; Sizofiran; Survival Analysis; Tegafur; Uracil; Uterine Neoplasms | 2002 |
3 trial(s) available for sizofiran and Ovarian Neoplasms
| Article | Year |
|---|---|
Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Prognosis; Prospective Studies; Sizofiran | 1993 |
[Combined effects of sizofiran and rG-CSF on myelosuppression in cancer chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Recombinant Proteins; Sizofiran; Thrombocytopenia | 1996 |
Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer--a preliminary trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Interferon-alpha; Interferon-gamma; Middle Aged; Ovarian Neoplasms; Recombinant Proteins; Sizofiran | 1992 |
8 other study(ies) available for sizofiran and Ovarian Neoplasms
| Article | Year |
|---|---|
Successful treatment of pseudomyxoma peritonei with intraperitoneal 10 per cent dextrose, sizofiran and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Doxorubicin; Female; Glucose Solution, Hypertonic; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Sizofiran; Treatment Outcome | 2002 |
[Concomitant intraperitoneal therapy with the antitumor polysaccharide Sizofiran and rG-CSF for ovarian cancer].
Topics: Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Parenteral; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Ovarian Neoplasms; Receptors, Interleukin-2; Sizofiran | 1993 |
[Induction of M-CSF and G-CSF receptor mRNA in peripheral blood mononuclear cells of gynecological cancer by sizofiran].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Female; Genital Neoplasms, Female; Humans; Leukocytes, Mononuclear; Ovarian Neoplasms; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; RNA, Messenger; Sizofiran; Uterine Cervical Neoplasms | 1993 |
Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cisplatin; Female; Ovarian Neoplasms; Rats; Rats, Inbred F344; Sizofiran | 1995 |
Maintenance of the activation of peritoneal macrophages in patients with ovarian cancer by sizofiran and recombinant interferon-gamma.
Topics: Adult; Combined Modality Therapy; Female; Humans; Injections, Intramuscular; Interferon-gamma; Macrophage Activation; Middle Aged; Ovarian Neoplasms; Peritoneal Cavity; Recombinant Proteins; Sizofiran | 1992 |
[Maintenance of the activation of peritoneal macrophage in patients with ovarian cancer by the repeated administration of sizofiran and interferon gamma].
Topics: Adult; Cystadenocarcinoma; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Injections, Intramuscular; Interferon-gamma; Interleukin-1; Macrophage Activation; Middle Aged; Ovarian Neoplasms; Peritoneal Cavity; Sizofiran; Tumor Necrosis Factor-alpha | 1991 |
[Effect of sizofiran or recombinant interferon gamma on the activation of human peritoneal macrophage function; an approach for the prophylaxis of intraperitoneal recurrence of ovarian cancer].
Topics: Adult; Drug Therapy, Combination; Female; Glycosaminoglycans; Humans; Interferon-gamma; Interleukin-1; Macrophage Activation; Macrophages; Middle Aged; Ovarian Neoplasms; Peritoneal Cavity; Peritoneal Neoplasms; Recombinant Proteins; Recurrence; Sizofiran | 1990 |
[Sizofiran and recombinant interferon gamma stimulate peritoneal macrophages obtained from patients with gynecologic malignancies--increased secretion of tumor necrosis factor, IL-1 and interferon-gamma].
Topics: Dinoprostone; Female; Glycosaminoglycans; Humans; Interferon-gamma; Interleukin-1; Macrophage Activation; Ovarian Neoplasms; Peritoneal Cavity; Recombinant Proteins; Sizofiran; Tumor Necrosis Factor-alpha; Uterine Neoplasms | 1990 |